ArticleJournal of inflammation research2026
Tocilizumab for the Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease in Children: Two Case Reports and Literature Review.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The correlation and auxiliary diagnostic value of gut microbiota and serological indicators with Kawasaki disease complicated by coronary artery lesions.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The treatment of intravenous immunoglobulin-resistant Kawasaki disease remains challenging. We report the clinical course and extended follow-up of two cases of intravenous immunoglobulin-resistant Kawasaki disease successfully treated with tocilizumab. This report includes a summary of the global literature on the use of tocilizumab for the treatment of Kawasaki disease. Case Presentation: Two children with intravenous immunoglobulin-resistant Kawasaki disease treated with tocilizumab at our institution since 2022 were retrospectively analyzed. Case 1 presented with complete Kawasaki disease manifestations. Despite intravenous immunoglobulin and glucocorticoid treatment, the condition remained uncontrolled. Cyclosporine did not result in improvements, and interleukin-6 levels increased. The fever subsided within 24 h after tocilizumab administration. The coronary artery dilation had returned to normal at day 77; however, an urticarial rash was observed following the third tocilizumab dose. Case 2 exhibited complete Kawasaki disease manifestations, complicated by a giant coronary artery aneurysm. The fever persisted despite treatment with aspirin, intravenous immunoglobulin, and glucocorticoids, and interleukin-6 levels increased markedly. The fever resolved within 24 h following tocilizumab administration. During a 3-year follow-up, no adverse drug reactions were observed and the dilated coronary artery decreased in size. Among the 14 patients reviewed in the literature, 10 had significantly elevated interleukin-6 levels. All patients achieved rapid fever resolution (within 48 h) following tocilizumab administration and favorable coronary outcomes: most (12/14) showed regression of dilation or no dilation during follow-up. Only one patient developed anaphylaxis after a one-time administration. Conclusion: Tocilizumab could be considered a potential therapeutic option for intravenous immunoglobulin-resistant Kawasaki disease. It is advisable to closely monitor interleukin-6 levels and coronary artery parameters throughout the clinical course, while maintaining a heightened awareness of the possible adverse events related to tocilizumab treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.